Adynxx to participate in symposium, present posters at EFIC Pain Congress 2017

SAN FRANCISCO, CALIF., May 19, 2017 – Don Manning, chief medical officer, and Julien Mamet, founder and chief scientific officer, will participate in an official satellite symposium at the upcoming European Federation of IASP Chapters (EFIC) Pain Congressin Copenhagen entitled “Preventing Chronic Post-Surgical Pain.” As part of the agenda, the panel will discuss novel approaches to preventing CPSP illustrated by the development path of Adynxx’s lead program, AYX1.

The symposium will be held from 1:00pm – 5:30pm on Monday September 4 at the Bella Center, Copenhagen.

For more information:
http://www.efic2017.kenes.com/scientific-information/pre-congress-satellite-symposia#.WZXE61F94zN

To register:
https://www.regonline.com/builder/site/Default.aspx?EventID=2028909

Drs. Mamet and Manning will also present three posters during the poster sessions Wednesday September 6, entitled:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF A PREOPERATIVE EGR1 DECOY (AYX1) FOR PAIN AFTER TOTAL KNEE ARTHROPLASTY (TKA)

INTRATHECAL ADMINISTRATION OF AYX2 DNA-DECOY PRODUCES A LONG-TERM PAIN TREATMENT IN RAT MODELS OF CHRONIC PAIN BY INHIBITING THE KLF6, KLF9 AND KLF15 TRANSCRIPTION FACTORS

RELATION BETWEEN THE PHARMACOLOGY AND PHARMACOKINETICS OF THE EGR1 DECOY AYX1 FOR THE PREVENTION OF POST-SURGICAL PAIN

About Adynxx

Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery and resolving established chronic pain conditions. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Adynxx’s lead compound, AYX1, is an investigational drug designed to reduce acute post-surgical pain and prevent the transition to persistent or chronic pain with a single administration at the time of surgery. Adynxx has successfully demonstrated clinical efficacy in two Phase 2 clinical studies of AYX1 and is currently enrolling a final Phase 2 study to prepare for Phase 3 initiation in 2018. Additional AYX drug candidate compounds designed to address a range of intractable neuropathic and inflammatory pain syndromes are also in active development.